Brief: Regeneron Q2 Adjusted EPS USD 14.29 Vs. IBES Estimate USD 10.3
30/07/2026 11:31
BRIEF-Regeneron Q2 Adjusted EPS USD 14.29 Vs. IBES Estimate USD 10.3 Jul 30 (Reuters) - Regeneron Q2 revenue USD 4,291 million vs. IBES estimate USD 3,816 million.
- Q2 EPS USD 12.23
- outlook FY capex USD 1,030-1,100 million
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement